INOVIO PHARMACEUTICALS, INC.
Customers
2
0 disclosed
Suppliers
0
None disclosed
Largest customer
—
No % disclosed
Named-customer revenue
—
No estimate available
Latest period
Dec 31, 2024
10-K filed 2025-03-18
Customers 2
Companies INO discloses as major customers, as a share of INO revenue. 0 active, 2 lapsed.
| Company | % of INO revenue | Est. revenue | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| ApolloBio Corporation Non-SEC ApolloBio Corporation |
100% | $217.8K | FY 2024-12-31 | +71.0pp | Lapsed Last seen 2024-12-31 |
10-K 2025-03-18 |
ApolloBio Corporation $ 217,756 100 % $ 245,056 29 % | ||||||
| AZN ASTRAZENECA PLC |
2% | $35.5K | FY 2021-12-31 | ±0.0pp | Lapsed Last seen 2021-12-31 |
10-K 2022-03-01 |
AstraZeneca $ 41,659 2 % $ 170,587 2 % $ 3,194,877 78 % During the year ended December 31, 2019, we derived 78% of our revenue from AstraZeneca. During the year ended December 31, 2018, we derived 75% of our revenue from ApolloBio and 23% of our revenue from AstraZeneca. | ||||||
Unnamed major customers
Disclosed without names in the fiscal year ending 2023-12-31. Identities are not inferred.
Alerts are coming
Get an email when INO's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.